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The Wnt pathway inhibitors DKK1 and sclerostin
(SOST) are important therapeutic targets in diseases
involving bone loss or damage. It has been appreci-
ated that Wnt coreceptors LRP5/6 are also impor-
tant, as human missense mutations that result in
bone overgrowth (bone mineral density, or BMD,
mutations) cluster to the E1 propeller domain of
LRP5. Here, we report a crystal structure of LRP6
E1 bound to an antibody, revealing that the E1 do-
main is a peptide recognition module. Remarkably,
the consensus E1 binding sequence is a close match
to a conserved tripeptide motif present in all Wnt
inhibitors that bind LRP5/6. We show that this motif
is important for DKK1 and SOST binding to LRP6
and for inhibitory function, providing a detailed struc-
tural explanation for the effect of the BMDmutations.
INTRODUCTION
The Wnt/b-catenin pathway is essential for processes of embry-
onic development through those of tissue renewal and homeo-
stasis in the adult. Signaling is initiated at the cell surface by
binding of the secreted Wnt to its coreceptors Frizzled (Fz) (Bha-
not et al., 1996) and low-density lipoprotein receptor-related
protein (LRP5/6) (Pinson et al., 2000; Tamai et al., 2000). Recruit-
ment of the very closely related (69% identical) LRP5 or LRP6
into this ternary complex (Bourhis et al., 2010; Tamai et al.,
2000) results in a series of events necessary for the recruitment
of Axin to the plasma membrane (Bilic et al., 2007; Noordermeer
et al., 1994; Tamai et al., 2004; Zeng et al., 2008; Zeng et al.,
2005), stabilization of b-catenin, and, ultimately, activation of
Wnt target gene expression (MacDonald et al., 2009).
Misregulated Wnt signaling is implicated in diseases ranging
from osteoporosis to cancer (Clevers, 2006; MacDonald et al.,
2009; Nusse, 2008; Polakis, 2007). Recently, this list has
expanded to include metabolic disorders (Mani et al., 2007)
and neurodegeneration (Caricasole et al., 2004; De Ferrari
et al., 2007). An especially clear link exists between mutationsStructure 19, 1433–1of the protein adenomatous polyposis coli (APC), which prevent
effective regulation of b-catenin levels, and colorectal cancers
(Kinzler et al., 1991; Nishisho et al., 1991; Polakis, 2007). Also
of particular note is the strong genetic relationship between
LRP5 and bone homeostasis. Loss-of-function mutations in
LRP5 cause the autosomal recessive disorder osteoporosis-
pseudoglioma syndrome (OPPG), characterized by low bone
mass, ocular defects and a predisposition to fractures (Gong
et al., 2001). Conversely, several families whose members
exhibit unusually high bone-mass density were found to carry
missense (BMD) mutations in LRP5 (Boyden et al., 2002; Rickels
et al., 2005; Whyte et al., 2004).
At the cell surface, Wnt/b-catenin signaling is regulated by two
groups of secreted proteins with distinct modes of action. The
secreted Frizzled-related protein (sFRPs) (Dann et al., 2001;
Hoang et al., 1996) and Wnt inhibitory factor (WIF) (Hsieh et al.,
1999) inhibit the Wnt/b-catenin pathway by directly binding to
the Wnt proteins. The second class of Wnt inhibitors is com-
posed of the structurally unrelated Dickkopf (DKK) (Glinka
et al., 1998; Seme¨nov et al., 2001) and WISE (SOSTDC1)/sclero-
stin (SOST) (Itasaki et al., 2003; Li et al., 2005b; Seme¨nov et al.,
2005) families of proteins. These proteins inhibit the Wnt/b-cate-
nin signaling pathway by directly competing with Wnt for binding
to LRP5 and LRP6 (Bafico et al., 2001; Seme¨nov et al., 2001).
Both DKK1 and SOST have been shown to be directly involved
in bone growth regulation. In particular, complete or partial loss
of SOST function is responsible for sclerosteosis or Van Buchem
diseases, respectively (Balemans et al., 2001, 2002); the unusu-
ally dense and strong bone observed in these conditions resem-
bles the BMD phenotype caused by LRP5 gain-of-function
mutations. DKK1 mutations causing comparable effects have
not been reported, although the function of DKK1 in murine
bone development is comparable to that of SOST (Li et al.,
2005a).
Several aspects of the DKK1 and SOST function remain
unresolved. In particular, it is not fully understood how these
inhibitors recognize LRP5/6, and accordingly, how mutations in
LRP5 affect their function. The LRP coreceptors have large
extracellular regions with a modular domain structure. Each
module (designated below as an E domain) consists of a
YWTD-class b-propeller followed by an EGF-like domain
(Springer, 1998). The four modules (E1–E4, or E1E4) are followed442, October 12, 2011 ª2011 Elsevier Ltd All rights reserved 1433
Table 1. Structural and Refinement Statistics for LRP6 E1 Domain Complexes
Complex LRP6E1-Fab LRP6E1-DKK1pep LRP6E1-SOSTpep
PDB code 3SOB 3SOQ 3SOV
Data collection SSRL71/ADSC Q315 007HF/Saturn 944+ CMCF108ID/MAR300
Space group C2 C2 C2
Unit cell a = 167.6 A˚, b = 83.3 A˚, c = 62.8 A˚,
a = 90 b = 112 g = 90
a = 103.3 A˚, b = 47.0 A˚, c = 68.8 A˚,
a = 90 b = 97.2 g = 90
a = 103.3 A˚, b = 46.9 A˚, c = 68.3 A˚,
a = 90 b = 97.4 g = 90
Resolution 30–1.9 A˚ 30–1.9 A˚ 30–1.27 A˚
Total number of reflections 217,270 888,814 340,026
Completeness 91.9 (57.7)a 98.0 (82.9)a 98.1 (96.5)a
Redundancy 3.8 (3.7) 3.5 (2.4) 3.8 (3.8)
I/s 21.3(3.8) 16.8 (2.3) 27.0 (2.3)
Rsymb 0.060 (0.333) 0.073 (0.454) 0.046 (0.585)
Refinement
Resolution range 30–1.9 A˚ 30–1.9 A˚ 30–1.27 A˚
Rcrystc/Rfreed 0.174/0.212 0.170/0.221 0.153/0.180
Nonhydrogen atoms 6187 2780 3050
Water molecules 486 266 339
Average B, overall 37.9 27.5 23.1
Protein 39.9 26.2 21.3
Water 44.7 36.9 33.5
Rmsd bond lengths 0.008 A˚ 0.004 A˚ 0.016 A˚
Rmsd angles 1.172 0.925 1.785
a Values in parentheses are of the highest resolution shell.
b Rsym = SjIhi - Ihj/SIhi, where Ihi is the scaled intensity of the ith symmetry-related observation of reflection h and Ih is the mean value.
c Rcryst = ShjFoh - Fchj /ShFoh, where Foh and Fch are the observed and calculated structure factor amplitudes for reflection h.
d Value of Rfree is calculated for 5% randomly chosen reflections not included in the refinement.
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DKK1 and SOST Recognition by LRP5/6by three LDL type A repeats (LDLa) before the transmembrane
segment. Recently, we reported that LRP6 is modular not only
in structure but in its central biochemical function, binding to
Wnt ligands (Bourhis et al., 2010; Gong et al., 2010). Rather
than having a single ‘‘Wnt site,’’ LRP6 has at least two. One of
these is in the N-terminal region E1E2, which binds, for example,
to WNT9B, while the other is in E3E4 and binds to WNT3A (Bour-
his et al., 2010). Based on patterns of Wnt antagonism by anti-
LRP6 antibodies, Wnts may be divided into three groups; the
largest of these includes WNTs 1, 2, 2B, 6, 8A, 9A, 9B, and
10B (Gong et al., 2010). Signaling in response to these Wnts is
inhibited by the antibody YW210.09, originally raised against
the antigen E1E2. Like the Wnt ligands, DKK1 binds to at least
two sites on LRP5/6 (Bourhis et al., 2010; Li et al., 2005b), ex-
plaining, at least conceptually, its broad spectrum of Wnt
inhibition.
We report here the first structures of a YWTD propeller from
the LRP receptor superfamily other than the prototype low-
density lipoprotein receptor (LDLr) (Jeon et al., 2001). The struc-
tures reveal the E1 domain of LRP6 to recognize a short linear
peptide sequence, and we find not only that this sequence is
present in structurally diverse Wnt pathway inhibitors that bind
to LRP5/6 but also that it is important for their function. The E1
binding motif in DKK1 defines a new DKK1 interaction domain
(in addition to the previously characterized CRD2 domain), and
on this basis we propose a two-site model for DKK1 recognition
of LRP5/6 and inhibition of Wnt signaling. Finally, our results1434 Structure 19, 1433–1442, October 12, 2011 ª2011 Elsevier Ltdshow that human BMD mutations involve LRP5 residues that
make direct contacts with peptide ligand (or are important for
structural integrity of the peptide binding pocket), explaining in
detail how these mutations disrupt inhibition of Wnt signaling
by SOST and DKK1.
RESULTS
The First b-Propeller of LRP6 Is a Peptide Recognition
Module
To better understand the mechanism of Wnt signaling inhibition
by the YW210.09 antibody, we attempted to cocrystallize the
Fab and the first two tandem b-propeller-EFG-like domains of
LRP6 (E1E2). After an extended incubation (and degradation of
E2), we obtained crystals of the E1 domain only in complex
with the Fab. The structure was determined by molecular
replacement and refined to 1.9 A˚ resolution (R/Rfree of 0.175/
0.220; Table 1). The architecture of the LRP6 E1 domain closely
resembles that of LDLr (Jeon et al., 2001). Indeed, the structures
superimpose with an rmsd of 0.83 A˚ over 245 Ca atoms (of 304
total), despite a sequence identity of only 36%. The interaction
between the EGF-like domain and the b-propeller is extensive,
exhibiting features similar to those observed in LDLr structures
(Jeon et al., 2001; Rudenko et al., 2002).
The antibody binds to a region at the top center of the
b-propeller (Figure 1A), an area that is frequently involved in
protein-protein interactions (Springer, 1998; Rudenko et al.,All rights reserved
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Figure 1. Crystal Structure of the LRP6 E1-YW210.09 Complex
(A) Overview of the interaction between LRP6 E1 (first b-propeller and following
EGF-like domain, in white and purple, respectively) and the Fab (light chain in
green, heavy chain in cyan). The backbone representation at bottom is shown
in the same orientation as the cartoon representation at top. The boxed region
is approximately that shown in part (B); note that the view in (B) is rotated about
more than one axis compared to (A) to best show the detailed interactions.
(B) Detailed view of the CDR H3 ‘‘NAVK’’ sequence interaction with LRP6
(same color scheme as A). Two well-defined water molecules are shown in
purple.
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DKK1 and SOST Recognition by LRP5/62002; Takagi et al., 2003). A prominent acidic patch occupies
roughly a third of the total surface area on this side of the
b-propeller but barely overlaps with the YW210.09 epitope (see
Figure S1A available online). The paratope is composed of resi-
dues from five of the six antibody CDRs (the exception is L2) (Fig-
ure S1B). Contacts formed by heavy chain CDRs represent 80%
of the buried surface area, with the long (17 residue) CDR H3
(Figure 1A) itself accounting for over 50%. In particular, the short,
contiguous sequence NAVK (100–100c; Kabat numbering) ex-
hibits an unusually significant degree of interaction with com-
plementary surfaces on the propeller (Figure 1B). Asn100 of
the antibody makes a pair of hydrogen bonds with Asn185 of
LRP6, forming a ‘‘handshake’’ interaction, while the Val100b
side-chain docks into a hydrophobic cavity in the center channel
of the b-propeller. Between these, LRP6 Arg141 is largely buried
at the interface where it interacts with the main-chain carbonylStructure 19, 1433–1of Asn100 and appears to integrate two hydrogen-bond
networks. The first of these is the Asn-Asn ‘‘handshake,’’ while
the second involves two bridging waters (Wat1 and Wat2) that
hydrogen bond to antibody main-chain amides of Val100b and
Lys100c and to LRP6 Ser96, Asp98, and Arg141 side chains.
Finally, the ε-amino group of Lys100c occupies a shallow cleft
on the acidic patch of LRP6, where it interacts with the LRP6
main-chain carbonyls of Val70 and Leu95 and the side-chain
carboxylates of Glu73 and Glu115.
This interaction between the CDR H3 ‘‘NAVK’’ sequence and
LRP6 E1 b-propeller is highly similar to the interaction reported
between laminin and another YWTD b-propeller, nidogen (Takagi
et al., 2003) (Figure 2). In both cases, the core binding motif is
‘‘NAV,’’ and these residues interact with the two propellers in
the same way. In particular, the interactions with Fab Asn100
have exact counterparts in the laminin-nidogen complex (Fig-
ure 2A), and in both cases the Val side chain enters a central
hydrophobic cavity. Nidogen and LRP6 each interact with a
charged residue outside of the core binding motif: in the case
of LRP6, this is the Lys of ‘‘NAVK’’ (i.e., Lys100c from the Fab,
Figure 2B), while in nidogen, it is the Asp of ‘‘DPNAV’’ from
laminin (Figure 2C). In contrast to LDLr, the central channels of
nidogen and LRP6 E1 are closed off from solvent by a Phe
residue held in place by a nearby Trp side chain, or ‘‘hydrophobic
shutter’’ (Takagi et al., 2003) (Figure S2). This feature is thought
to distinguish YWTD propeller domains that can bind to low
molecular-weight ligands, and, based on sequence, it would
appear that multiple propellers from the Wnt coreceptors LRP5
and LRP6 might resemble nidogen in this respect (Takagi
et al., 2003) (Figure S2C). However, it was not anticipated that
LRP5/6 and nidogen would recognize the same core binding
motif.
To discover optimal binding sequences for LRP6 E1, we used
peptide phage display. Peptide sequence motifs are remarkably
consistent with the binding motif observed in the antibody
complex structure. For peptides selected from both linear
(Figure 3) and cyclic peptides libraries (Figure S3), an invariant
Asn is present (position 0). At position + 2, there is a branched
hydrophobic residue, with Ile rather than Val being present in
the overwhelming majority of cases. A basic residue (most often
Lys) is generally present at position +3, but this preference varies
somewhat for different cyclic sequence subgroups (Figure S3).
Affinities (IC50 values) for representative linear peptides were in
the low micromolar range, while affinities of cyclic peptides
ranged from low micromolar to submicromolar (not shown).
The strong selection for this short motif confirms that the E1
propeller recognizes a specific linear sequence.
A Short Peptide Motif Is Important for Binding
of DKK1 and SOST to LRP6 E1
A sequence present in human DKK1 (NAIKN; amino acids 40–44)
is very similar to themotif found in the CDRH3 loop of YW210.09
and to the preferred LRP6 E1 binding motif identified by phage
display. The motif is present in multiple DKK proteins (Figure 4A)
and is conserved among species (Figure S4A). This N-terminal
region of DKK1 precedes the two predicted cysteine-rich
domains (CRDs) and, unlike the CRDs, has not been identified
previously as functionally important (Brott and Sokol, 2002). A
similar motif appears in two other proteins regulating Wnt442, October 12, 2011 ª2011 Elsevier Ltd All rights reserved 1435
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Figure 3. Preferred E1 Binding Motif Determined by Selection of
Linear Peptide Phage Libraries for Clones Binding to LRP6 E1E2 as
Described in Supplemental Experimental Procedures
The motif shown is derived from 145 sequenced phage clones, each of which
binds to E1 but not to E2. Related disulfide-cyclized binding motifs are shown
in Figure S3.
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Figure 2. Peptide Recognition by LRP6 E1 and Nidogen (PDB code:
1NPE)
Peptides from the protein complex structures are shown in contrasting colors
(green and yellow for antibody and laminin, respectively) Propeller domains
shown at right are all in the same relative orientation, while peptides at left are
oriented to best show details of interactions. Structures were overlaid using
residues from the core binding motif of the ligands (NAV, in each case) and five
binding site residues from the propellers (LRP6 A54, R141, N185, F228, and
W242 and the structurally equivalent nidogen residues).
(A) A conserved set of hydrogen bonds defines the conformation of the
invariant Asn residue of the core binding motif ‘‘NAV.’’ The side chain forms
a ‘‘handshake’’ interaction with N185 (LRP6) or N1082 (nidogen), while the
main-chain carbonyl is positioned by a bifurcated interaction with R141 (LRP6)
or R1037 (nidogen). A comparison of the overall propeller structures is shown
at right. Other than the lack of an EGF-like module for nidogen, the overall
architecture is very similar. The blades of the propellers overlay closely;
differences can be seen in the conformations of surface loops.
(B) Specificity determinants in the LRP6 ligand pocket. The sequence ‘‘NAVK’’
from the antibody is shown with interacting residues from LRP6 labeled. E73
and E115 interact with the antibody Lys. At right is a surface representation of
LRP6 showing the location of the peptide recognition pocket and the distri-
bution of surface charge.
(C) Specificity determinant in the nidogen ligand pocket. The sequence
‘‘DPNAV’’ from laminin is shown with interacting residues from nidogen
labeled. The Asp is critical for high-affinity peptide binding (Po¨schl et al., 1994)
and forms salt bridging interactions with nidogen R1055. Equivalent Arg
residues are not present in LRP5 or LRP6. At right is a surface representation of
nidogen showing the location of the peptide recognition pocket and the
distribution of surface charge.
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1436 Structure 19, 1433–1442, October 12, 2011 ª2011 Elsevier Ltdsignaling via interaction with LRP5/6, namely SOST (Seme¨nov
et al., 2005) and WISE (Itasaki et al., 2003) (Figure 4A; Fig-
ure S4A). SOST and WISE are highly similar and belong to the
superfamily of cystine-knot proteins (McDonald and Hendrick-
son, 1993); the motif occurs in the extended loop 2, also called
the ‘‘heel’’ (Lintern et al., 2009; Veverka et al., 2009). In the
case of SOST, the ‘‘heel’’ is the binding epitope for a neutralizing
antibody (Lintern et al., 2009). Based on the aligned sequences,
the core motif would appear to be ‘‘NXI,’’ where ‘‘X’’ is a small
residue (Ala, Ser) or Trp.
The presence of this motif suggests that the inhibitory proteins
might bind with high affinity to the first b-propeller of LRP5/6. To
test this, we first mapped the interactions of SOST, DKK1, and
DKK2 with various propeller constructs of LRP6 using purified
proteins (Figure S4B). These data indicate that SOST binds to
the E1 domain only (recognizing E1E4, E1E2, and E1 but not
E2, E4, or E3E4). A similar conclusion has been reached from
antibody competition studies (Ettenberg et al., 2010). In contrast,
DKK1 and DKK2 appear to have two independent binding sites
(Bourhis et al., 2010; Li et al., 2005b) on the E1 and E3 domains
(each recognizing E1E4, E1E2, E3E4, and E1 but not E2 or E4).
Significantly, we find that both SOST and DKK1 bind tightly to
a common site on the E1 domain (Figure S4C), supporting the
idea that the interactions might be driven by the ‘‘NXI’’ peptide
motif.
We next asked whether 7 mer peptides taken from DKK1,
SOST, or WISE bind to LRP6 E1E2. The DKK1 peptide binds
with relatively high affinity (IC50 = 6 mM), similar to the affinity of
the best of our linear phage-selected peptides and to that of a
laminin peptide for the nidogen b-propeller (Po¨schl et al.,
1994), while the SOST and WISE peptides bind a few-fold
more weakly (Figure S4D). Truncation of the DKK1 peptide re-
vealed the tetrapeptide Ac-NAIK-am to be the shortest peptide
binding with significant affinity (Table S1).
To understand the interactions in detail, we determined high-
resolution structures of DKK1 and SOST peptides in complex
with LRP6 E1. (Figure 4B). Remarkably, the peptides (especially
the DKK1 peptide) show bound-state conformations very similar
to that of the antibody loop. In addition to the core ‘‘NXI’’ motif,
basic side chains in each peptide interact with the acidic patchAll rights reserved
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Figure 4. Wnt Inhibitors Contain an ‘‘NXI’’ Motif Important for
Binding to the E1 Domain
(A) Alignment of motifs from DKK proteins, SOST, and WISE with the antibody
H3 loop and the consensus motif from phage display. (Phage peptide residues
shown in lighter shade are commonly seen but not as highly conserved as
those shown in black; see Figure 3.)
(B) Overlay of cocrystal structures of DKK1 (cyan; 1.9 A˚) and SOST (green;
1.3 A˚) 7 mer peptides shown in (A) bound to the LRP6 E1 domain (surface
representation; the ‘‘acidic patch’’ is the large red area at right). For clarity, the
first two residues of each peptide are not shown. The gray sphere is a bound
calcium ion.
(C) The Asn and Ile residues of the ‘‘NXI’’ motif are important for DKK1 and
SOST binding to LRP6 E1E2. Affinities were measured by biolayer interfer-
ometry and are shown relative to the affinity of the corresponding wild-type
protein. Errors shown are ± standard deviation for three or more experiments.
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DKK1 and SOST Recognition by LRP5/6on LRP6, despite their different relative positions in the
sequence. For the DKK1 peptide, Lys immediately follows the
Ile residue and occupies a small acidic cleft in a manner very
similar to the antibody Lys. In the case of the SOST peptide,
the Ile is followed by an intervening Gly before the basic Arg
residue. This reorients the peptide backbone and places the
Arg side chain in a more peripheral location on the acidic patch
of LRP6 (Figure 4B).
The combined results of the peptide and domain mapping
studies suggested that binding of DKK1 and SOST to LRP6 E1
might be mediated primarily by the ‘‘NXI’’ motif present in each
protein. To test this idea, the Asn and Ile residues in each protein
were substituted with amino acids predicted to disrupt the inter-
action. The N40A substitution in DKK1 resulted in a 75-fold loss
in affinity for LRP6 E1E2, while the I42E substitution largely abol-
ished binding (>367-fold effect) (Figure 4C; Figure S4E). The
impact of the substitutions on SOST binding is clearly evident
but not as strong, with 14- and 19-fold losses in affinity for the
N117A and I119E substitutions, respectively (Figure 4C; Fig-Structure 19, 1433–1ure S4E). These data are consistent with an important role for
the ‘‘NXI’’ motif, especially for DKK1.
SOST Inhibits Only a Subset of Wnts while DKK1 Is More
Broadly Active
As described above, SOST binds to LRP6 E1 and does not
interact with the E3E4 region of LRP6. WNT9B also binds to
the E1E2 region but not to the E3E4 region (Bourhis et al.,
2010). Accordingly, SOST inhibits WNT9B binding to LRP6
E1E4 (Figure S5A). In contrast, SOST does not inhibit the binding
of WNT3A to LRP6 E1E4 (Figure S5A), in agreement with our
previous observation that WNT3A does not bind to E1E2 but
instead binds to the E3E4 region of LRP6 (Bourhis et al., 2010).
Based on antagonism by the YW210.09 antibody (Gong et al.,
2010), we might expect that, in addition to WNT9B, signaling in
response to WNTs 1, 2, 2B, 6, 8A, 9A, and 10B would be antag-
onized by SOST, consistent with SOST and the antibody binding
to a common site on E1.
The situation with DKK1 is more complex, as DKK1 can bind
with high affinity to both E1E2 and E3E4 fragments of LRP6
(Bourhis et al., 2010; Li et al., 2005b). Accordingly, DKK1 inhibits
the binding of both WNT3A and WNT9B to LRP6 E1E4 (Fig-
ure S5A). Our data on the importance of the N-terminal region
of DKK1 can be combined with previous observations to define
a model for DKK1 function in which two distinct sites on DKK1
bind to two independent sites on LRP6.
An important role for the C-terminal region of DKK proteins
(CRD2) has been known for some time; for example, it has
been shown that mRNAs encoding human DKK1 or DKK2 lack-
ing the first cysteine-rich domain (CRD1) can inhibit wnt8a
signaling when injected into Xenopus embryos (Brott and Sokol,
2002). Based on a model derived from computationally docking
an NMR structure of CRD2 from mouse DKK2 onto a homology
model of LRP5 E3 (Chen et al., 2008), several substitutions were
predicted to impair mouse DKK1 function (H210E, K217E or
R242E; these positions correspond to human DKK1 residues
204, 211, and 236, respectively) (Chen et al., 2008). In each
case, the substitutions disrupted both binding to cells trans-
fected with LRP6 and DKK1 inhibition of WNT3A signaling
(Wang et al., 2008). We suspected that these effects might be
driven specifically by loss of affinity for E3E4 andmight therefore
apply only to DKK1 inhibition of Wnts binding to this region of the
coreceptor (e.g., WNT3A).
We tested this idea with DKK1 mutants H204E and K211E.
Indeed, these substitutions interfered with binding to LRP6
E3E4 but not to E1E2 (Figure 5A). Extending results shown above
(Figure 4C), the converse was true for ‘‘NXI’’ motif substitutions
(Figure 5A). Interestingly, neither CRD2 nor ‘‘NXI’’ motif substitu-
tions had more than a slight effect on DKK1 binding to E1E4
(Figure 5A). Taken together, this suggests that DKK1 binds inde-
pendently to two different sites on E1E4 (2:1 complex; cartoon 3
in Figure S4B), or alternatively, that DKK1 can bind to two sites
that are mutually exclusive (i.e., alternative 1:1 complexes;
cartoons 5 and 6 in Figure S5B). A third possibility is that a single
DKK1 molecule bridges sites on E1 and E3 (simultaneous
binding, cartoon 4 in Figure S5B); however this seems less likely,
as there is little evidence of avidity contributions to affinity from
interaction at two sites (compare DKK1 affinity for E1E4 to that
for E1E2 or E3E4 shown in Figure S4B, or the relative insensitivity442, October 12, 2011 ª2011 Elsevier Ltd All rights reserved 1437
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Figure 5. DKK1 Has Two Independent and Functionally Important
Binding Regions, One that Recognizes LRP6 E1E2 and One that
Recognizes LRP6 E3E4
(A) Effects of substitutions in the DKK1 ‘‘NXI’’ motif (N40A, I42E) or in CRD2
(H204E, K211E) on binding to LRP6 propeller constructs. Errors shown are ±
standard deviation for three or more experiments.
(B) Inhibition of Wnt1 signaling by DKK1 and SOST variants. Cells were
transfected by WNT1 (binds to LRP6 E1E2), and inhibitors were used at the
indicated doses. Data are shown as percentage of inhibition for the average of
triplicate samples (±standard deviation) relative to the average induction by
WNT1 in the absence of added inhibitor.
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DKK1 and SOST Recognition by LRP5/6of E1E4 binding to disruption of a single interaction shown in
Figure 5A). Furthermore, we have been unable to show formation
of a ternary complex of E1E2, DKK1, and E3E4 (Bourhis et al.,
2010).
To distinguish 2:1 and 1:1 bindingmodels, complexes of DKK1
variants with E1E4 were analyzed by size-exclusion chromatog-
raphy coupled with light-scattering detection (SEC-MALS).
These experiments indicate that all of the DKK1 complexes
with LRP6 E1E4 exhibit 1:1 stoichiometry (Figure S5B), in agree-
ment with a crosslinking study of wild-type DKK1 binding to
cell-surface LRP6 (Bafico et al., 2001). Overall, the affinity
measurements and light-scattering data suggest the existence
of two independent, but mutually exclusive, binding modes
between DKK1 and LRP6.
To test the relevance of this model to cellular signaling, we
compared inhibition by DKK1 and SOST variants in a Wnt-de-
pendent TOPbrite luciferase reporter assay (Gong et al., 2010;
Zhang et al., 2009). Cells stably transfected with reporter were
transfected transiently withWNT1, and effects on reporter induc-
tion were measured (Figure 5B). For wild-type DKK1 and SOST,
strong inhibition of WNT1-dependent signaling is observed. This
is consistent with assignment of WNT1 to a class of SOST-sensi-
tive Wnts signaling through the E1E2 portion of LRP5/6 as1438 Structure 19, 1433–1442, October 12, 2011 ª2011 Elsevier Ltddescribed above. The DKK1 and SOST mutants show activities
consistent with their binding to LRP6 (Figure 5B). SOST I119E
(‘‘NXI’’ motif) is impaired relative to wild-type in its ability to inhibit
WNT1-driven signaling, as is DKK1 I42E. In contrast, DKK1
K211E (CRD2) efficiently inhibits WNT1 signaling, consistent
with the retained ability of this mutant to bind to E1E2 (Figure 5A).
Reciprocal inhibition patterns are observed when treating cells
stimulated by WNT3A (Figures S5C and S5D).
Taken together, the binding data and the effects on Wnt
signaling confirm that the conserved ‘‘NXI’’ motif is functionally
relevant for DKK1 and SOST inhibition of those Wnts signaling
through binding to E1E2, and that the DKK1 CRD2 interaction
with E3E4 is important only for inhibition of a different subset
of Wnt ligands. In addition, the data show that DKK1 inhibits
Wnt signaling broadly (through two distinct binding modes),
while SOST is more selective. Finally our data support previous
conclusions regarding the importance of the LRP5/6 E1 propeller
(in addition to the E3 propeller) in conferring sensitivity to DKK1
inhibition (Ai et al., 2005; Binnerts et al., 2009).
Human Bone Mineral Density (BMD) Mutations
and ‘‘NXI’’ Peptides Disrupt Binding of DKK1
and SOST to LRP6 E1 without Blocking WNT9B
Understanding the DKK1 and SOST interaction with the first
b-propeller of LRP6 sheds light on the mechanism of LRP5
gain-of-function mutations. These single amino acid substitu-
tions in LRP5 E1 lead to significant increases in bone strength
and thickness in affected individuals (Boyden et al., 2002; Rick-
els et al., 2005; Whyte et al., 2004). Nine LRP5 gain-of-function
mutations (at seven amino acid positions) have been described
(Rickels et al., 2005; Figure 6A). Each of these residues is strictly
conserved between LRP5 and LRP6 (Figure S6), and, signifi-
cantly, the top interacting surfaces of the E1 propellers are
almost entirely identical (Figure 6B), supporting the use of
LRP6 as a surrogate for LRP5. Mapping the sites of BMD muta-
tions onto the LRP6 E1 DKK1 peptide complex (and using LRP5
numbering; Figure 6C), the most structurally striking of the BMD
mutations are N198S andR154M; Asn198 engages in the ‘‘hand-
shake’’ interaction with the invariant Asn of the ‘‘NXI’’ motif, while
Arg154 positions the carbonyl of the same peptide residue.
Overall, the BMD mutation sites are close in space or primary
sequence to the bound peptide or to key elements of the peptide
binding pocket. The main-chain carbonyl of Ala242 hydrogen
bonds to the amide of Thr253, and the side-chain hydroxyl of
Thr253 (present in one of the conserved ‘‘YWTD’’ repeats)
hydrogen bonds to the main-chain amide of Ala242. These inter-
actions position Trp255 and Phe241 of the ‘‘hydrophobic
shutter.’’ In addition, Ala242 is immediately beneath Phe241,
also potentially impacting the position of the phenyl ring. The
indoles of Trp170 and Trp196 make up two walls of the pocket
surrounding the Asn-Asn ‘‘handshake.’’ These are flanked by
BMD sites Gly171 and Ala214, respectively. Mutations G171R,
G171V, A214T, and A214Vmight be expected to alter the confor-
mations of the surface loops in which they occur, thereby dis-
turbing the positioning of the indole side chains. The importance
of these indole side chains in forming the peptide-interaction
pocket is supported by the recent discovery of a humanmutation
in the equivalent of Trp170 in the third b-propeller of LRP4
(W1186S) that disrupts interaction with SOST (Leupin et al.,All rights reserved
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Figure 6. LRP5 Gain-of-Function (BMD) Mutation Sites
Define the ‘‘NXI’’ Binding Pocket
(A) BMD sites (shown with LRP5 numbering) mapped onto the
structure of LRP6 E1. These correspond to conserved LRP6
residues D98, R141, G158, N185, A201, A229, and T240.
(B) Surface representation of LRP6 E1 showing the CDR H3
sequence ‘‘NAVK’’ in cyan. At left, residues in LRP6 that are
identical in LRP5 are shown in white, while nonidentical residues
are shown in yellow. The representation at right is the same,
except that extremely conservative differences (K/R, D/E, F/Y, or
aliphatic substitutions) between LRP5 and LRP6 are also colored
white.
(C) Detailed interactions of BMD residues with ligand. LRP6 E1
(LRP5 numbering) is shown in complex with the DKK1 peptide
(‘‘NAIK’’ only, in white). BMD sites are shown in yellow with the
‘‘hydrophobic shutter’’ in cyan (see Figure S2). Two Trp residues
that define the Asn binding pocket are shown in green.
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DKK1 and SOST Recognition by LRP5/62011). Finally, Asp111 orients a keywater molecule in the binding
site (see Asp98 in Figure 1B) and is adjacent to the peptide Ile
residue. Accordingly, the BMD phenotype would appear to be
the specific consequence of a failure of LRP5 to bind to the
‘‘NXI’’ sequences in the inhibitory proteins.
Cells transfected with LRP5 variants carrying BMD mutations
show reduced binding to SOST and are less sensitive to SOST
inhibition of WNT10B or WNT6 signaling (Semenov and He,
2006). To further test the effects of the BMD substitutions in
our assays, we introduced several of them into LRP6 E1E2.
(LRP6 E1E2 G158V could not be expressed in insect cells; the
corresponding LRP5 mutant G171V expresses at extremely
low levels in mammalian cells [Semenov and He, 2006].) All of
the LRP6 mutations we tested disrupt the binding of bothStructure 19, 1433–1442, OctobDKK1 and SOST to LRP6 E1E2 (Figure 7A). In contrast,
there is little to no effect on the binding of WNT9B
binding to the LRP6 variants (Figure 7A). These results
support the idea that the gain of function resulting from
BMD mutations does not result from a gain in affinity
for Wnt ligands (or from enhancedWnt signaling (Ellies
et al., 2006; Ai et al., 2005, Semenov and He, 2006)),
but instead from a selective loss in affinity for Wnt
inhibitors. Importantly, we not only confirm that
binding to SOST is affected (Ellies et al., 2006; Seme-
nov and He, 2006), but also show, in accord with
previous cellular studies (Ai et al., 2005), that binding
of DKK1 to its E1 interaction site is impaired.
To extend the conclusions from protein mutagen-
esis, peptides were assayed for inhibition of binding
of various ligands to LRP6. The DKK1 peptide and
two higher affinity cyclic peptides inhibited binding of
the inhibitors DKK1 and SOST to LRP6 E1E2 with
very little effect on binding of WNT9B (Figure 7B).
The minimal effect on Wnt binding suggests that Wnt
ligands must bind to a site other than the center of
the b-propeller; this is consistent with the lack of
‘‘NXI’’ motifs in Wnt ligands and the comparative
insensitivity of Wnt binding to BMD substitutions.
However, the Wnt site must be close to the peptide
site because the larger protein inhibitors DKK1,
SOST, and the YW210.09 antibody all bind to thissite and block WNT9B binding to LRP6 (Bourhis et al., 2010;
Gong et al., 2010).
DISCUSSION
Bone loss is a serious medical problem, not only during post-
menopausal osteoporosis, but also in rheumatoid arthritis.
Bone is degraded in multiple myeloma and in bone metastases.
Therapeutic strategies aimed at strengthening bone, fracture
prevention, or restoration of damaged bone are therefore of
very high interest (Kawai et al., 2011; Mason and Williams,
2010). The Wnt pathway inhibitors DKK1 and SOST, because
of their roles in suppressing new bone formation, are consid-
ered highly promising therapeutic antibody targets; indeed,er 12, 2011 ª2011 Elsevier Ltd All rights reserved 1439
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Figure 7. ‘‘NXI’’ Peptides Mimic the Effect of BMDMutations, Differ-
entiating the Binding Site for WNT9B from Those of SOST and DKK1
(A) LRP5BMD substitutions introduced into LRP6 E1E2 (indicated on the y axis
in LRP6 numbering). Binding to DKK1, SOST, and WNT9B was assessed by
biolayer interferometry.
(B) Effect of LRP6 E1-binding peptides on binding of Wnt inhibitors and
WNT9B. Immobilized LRP6 E1E2 was exposed to protein ligand (WNT9B,
DKK1, or SOST) present in solution at 3 3 Kd for E1E2. Competing peptides
were added at 203 IC50 (determined by competition phage ELISA). Peptide A
(from DKK1): Ac-NSNAIKN-am; Peptide B: Ac-CNSIKFCG-am (disulfide,
IC50 = 0.8 mM); Peptide C: Ac-GSLCSNRIKPDTHCSS-am (disulfide, IC50 =
0.5 mM).
Errors shown are ± standard deviation for three or more experiments.
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DKK1 and SOST Recognition by LRP5/6antibodies neutralizing the function of SOST show significant
preclinical activity (Ominsky et al., 2010) and are now in human
clinical trials (Padhi et al., 2011).
We show here that the structurally unrelated proteins DKK1
and SOST recognize the first b-propeller domain (E1) of the
Wnt coreceptors LRP5/6 through a shared interaction motif.
Remarkably, this is a short linear peptide ‘‘NXI’’ that binds to
the center of the E1 propeller, and we show that interaction
with this segment of DKK1 and SOST peptide is important in
both cases for inhibitory function. The functional importance of
peptide recognition is underscored by the clustering of human
BMD mutations to the LRP5 E1 peptide binding pocket and
the direct interactions these residues form with bound peptide
(Figure 6C).
LRP4/MEGF7 has emerged recently as a third receptor for
DKK1 and SOST (Choi et al., 2009). LRP4 shares the four tandem1440 Structure 19, 1433–1442, October 12, 2011 ª2011 Elsevier LtdYWTD propeller/EGF-like domain structure of LRP5/6 but is
otherwise organized differently (Herz and Bock, 2002). Two
human missense mutations producing a sclerosteosis-like
condition occur in the third propeller domain (E3) of LRP4 and
impair binding of LRP4 to SOST (Leupin et al., 2011). These sites
are R1170, the structural equivalent to LRP5 E1 residue R154
and W1186, equivalent to LRP5 W170 (Figure 6C). The fact
that LRP4 mutations occur in residues that form the peptide
binding pocket in LRP5/6 suggests strongly that LRP4 E3 recog-
nizes a peptide sequence in SOST in the sameway as seen in our
LRP6 E1 structures.
Recognition of an Asn-anchored peptide motif may be
a general mode of ligand binding by YWTD b-propeller proteins.
In the first reported ligand complex structure from this family
(Takagi et al., 2003), the nidogen propeller was found to re-
cognize a sequence in laminin very similar to the E1 binding
motif we describe here (Figure 2). For the LRP4/5/6 E domains,
the Arg residue equivalent to LRP5 R154 is present in 12 of 12,
while the Asn equivalent to LRP5 N198 is present in 10 of 12
(the exceptions being the E4 modules of LRP5/6), indicating
that the most critical Asn-anchoring features (Figure 2A) are
generally conserved. It remains to be determined how many of
these E domains might recognize short peptides and their
detailed sequence preferences. Conceivably, other interactions
in the Wnt signaling pathways will be driven by imbedded
peptide ligands recognizing particular E domains in the LRP
receptors.
The unexpected finding that Wnt inhibitors SOST and DKK1
act through a common mechanism has interesting implications
for drug discovery targeting bone-loss disorders. Unlike the
neutralizing SOST antibody, a small molecule binding to the
‘‘NXI’’ site of LRP5/6 might counteract both SOST and DKK1.
Furthermore, molecules binding selectively to LRP5, to LRP6,
or even to LRP4 could offer different (and possibly beneficial)
activity profiles compared to pan-LRP ligands. Humans
carrying LRP5 BMD mutations have markedly enhanced bone
density and strength (Boyden et al., 2002; Rickels et al.,
2005; Whyte et al., 2004). These patients exhibit complications
related directly to bone overgrowth but do not suffer from
gross developmental abnormalities nor, apparently, an in-
creased risk of cancer (Mason and Williams, 2010). This
genetic validation and our finding of a small binding pocket
together indicate that LRP5/6 E1 is a promising target for
drug discovery.
EXPERIMENTAL PROCEDURES
Proteins and Crystallography
Purified WNT3A and WNT9B were obtained from R&D Systems (Minneapolis,
MN). All DKK1, SOST, and LRP6 variants were expressed in insect cells as
previously described (Bourhis et al., 2010). Biotinylated proteins for binding
studies were prepared by coinfection with a virus expressing biotin ligase as
previously described (Bourhis et al., 2010). Proteins were purified by Ni-NTA
affinity chromatography followed by gel filtration. YW210.09 Fab was ex-
pressed in Escherichia coli and affinity purified as described in Supplemental
Experimental Procedures. The E1-Fab complex crystal was obtained from
crystallization trials conducted on E1E2-Fab complex, while E1-peptide
complex structures were obtained by crystallization of E1 domain in the
presence of excess DKK1 peptide; full details of complex crystallization,
data collection, and structure determination are given in Supplemental Exper-
imental Procedures.All rights reserved
Structure
DKK1 and SOST Recognition by LRP5/6Protein Affinity Measurements
Protein-protein interaction affinities were measured by biolayer interferometry
using an Octet Red instrument (ForteBio) as previously described (Bourhis
et al., 2010). Errors shown are ± standard deviation for three or more
experiments.
Cellular Assays
The luciferase reporter assay in HEK293s cells transfected byWNT1 was per-
formed as described (Gong et al., 2010; Zhang et al., 2009). Purified inhibitors
were added as indicated.
ACCESSION NUMBERS
Atomic coordinates and structure factors for the reported crystal structures
have been deposited with the Protein Data Bank under accession codes
3SOB (LRP6 E1/Fab complex), 3SOQ (LRP6 E1/DKK1 peptide complex),
and 3SOV (LRP6 E1/SOST peptide complex).
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures, two tables, and Supplemental
Experimental Procedures and can be found with this article online at
doi:10.1016/j.str.2011.07.005.
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